MORRIS PLAINS, N.J., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that the Company will participate in the Brean Capital 2012 Life Sciences Summit on Wednesday, November 7, 2012 at the Sentry Centers in New York City. This conference will feature small group sessions and one-on-one meetings with institutional clients. There will be no formal presentation.
